Latest Breaking News On - அம்பிகை ஷர்மா - Page 5 : comparemela.com

Himachal to start vaccinating people between 18 and 44 on May 17

Solan, May 14 Himachal Pradesh will begin vaccinating people between 18 and 44 from May 17, officials said on Friday. The development came after sources in the state government said the state received 1,07,620 doses from sources other than the central government. The National Health Mission has issued directions to chief medical officers to organise vaccination programmes for this age group only on Mondays and Thursdays. These vaccination programmes will only cater to 100 beneficiaries at a time. Beneficiaries will be informed of their turn two days in advance. Beneficiaries must register for the vaccination programme beforehand. There will be no on-site registrations. The state government has planned some 1,070 sessions in all 12 districts of the state. Of this, 228 will be held in Kangra, the largest district and also the most affected by the pandemic. The rest dividebd thus: Mandi (154); Shimla (136); Solan (98); Sirmaur (82); Una (79); Chamba (78); Kullu (71); Hamirpur

Himachal pradeshUttar pradeshMadhya pradeshAmbika sharmaSuperintendents of policeTribune news serviceNational health missionDeputy commissionersஇமாச்சல் பிரதேஷ்உத்தர் பிரதேஷ்மத்யா பிரதேஷ்அம்பிகை ஷர்மாகண்காணிப்பாளர்கள் ஆஃப் போலீஸ்ட்ரிப்யூன் செய்தி சேவைதேசிய ஆரோக்கியம் பணிதுணை ஆணையர்கள்

Sputnik vaccine to cost Rs 995 per shot

Solan, May 14 Russian-made Covid-19 Sputnik V vaccine received the regulatory clearance from the Kasauli-based Central Drugs Laboratory (CDL) on for its first consignment of imported doses that had arrived in India on May 1. As part of a limited pilot, the soft launch of the vaccine has commenced and the first dose of the vaccine was administered in Hyderabad on Friday. “The lab had tested Sputnik V samples received by it on May 3 for toxicity, sterility and other key factors. Its report was sent to the Drug Controller General of India (DCGI) last evening after completion of the testing.” informed a source in the lab.

Andhra pradeshHimachal pradeshAmbika sharmaNational covidCentral drugs laboratoryTribune news serviceRussian direct investment fundNational regulations of vaccinesKasauli based central drugs laboratoryDrug controller generalNational regulationsஆந்திரா பிரதேஷ்கச ul லிஇமாச்சல் பிரதேஷ்அம்பிகை ஷர்மாமைய மருந்துகள் ஆய்வகம்

In Himachal, Covid -ve report must for industrial labour rejoining work

In Himachal, Covid -ve report must for industrial labour rejoining work
tribuneindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tribuneindia.com Daily Mail and Mail on Sunday newspapers.

Himachal pradeshMahinder palAmbika sharmaTribune news serviceஇமாச்சல் பிரதேஷ்மஹிந்தர் நண்பாஅம்பிகை ஷர்மாட்ரிப்யூன் செய்தி சேவை

Environment not conducive to host IPL 2021-like events: Ambika Sharma

While we stare at huge losses be it sponsors, broadcasters, BCCI, the environment is not conducive to host IPL 2021 or similar matches any more, says Ambika Sharma, Founder & MD of Pulp Strategy. The Indian Premier League (IPL) 2021 came to an abrupt halt earlier in the week after a number of players and support staff tested positive for COVID-19. The bio-security bubble buckled and the Board of Control for Cricket in India (BCCI) suspended IPL 2021 for the health and safety of everyone. In this regard, Ambika Sharma, Founder & MD of Pulp Strategy, tried to see the kind of impact IPL 2021 suspension will have on similar events in the near future as well as on the country’s image:

Ash shariqahUnited arab emiratesAbu dhabiAmbika sharmaIndian premier leaguePulp strategyLaliga spainஒன்றுபட்டது அரபு அமீரகங்கள்அம்பிகை ஷர்மாஇந்தியன் ப்ரிமியர் லீக்கூழ் மூலோபாயம்

Himachal Pradesh institute s antiserum trials show +ve results : The Tribune India

2367 Ambika Sharma Solan, May 4 Kasauli-based Central Research Institute (CRI) has manufactured an antiserum which has been found effective in neutralising the Covid virus, including its mutant strains. The test was conducted by the National Institute of Virology (NIV), Pune. Neutralises virus Antiserum is human or nonhuman blood serum containing polyclonal antibodies used to provide passive immunity against many diseases Added protection It will provide an additional protection to critical Covid patients and help reduce mortality The CRI had begun working on the antiserum in April last year in collaboration with the Indian Council of Medical Research. Institute director Dr Ajay Tahlan said, “The test result is heartening. It will pave the way for further trial. A lot of work was involved in manufacturing the antiserum. Horses were inoculated with dead virus provided by the NIV and antibodies were developed. The antiserum was then sent to Pune for testing.”

Ambika sharmaAjay tahlanCentral research instituteNational institute of virologyNational institute of nutritionIndian council of medical researchCentral drug laboratoryTribune news serviceNational instituteIndian councilHyderabad based national instituteஅம்பிகை ஷர்மாமைய ஆராய்ச்சி நிறுவனம்தேசிய நிறுவனம் ஆஃப் வைராலஜிதேசிய நிறுவனம் ஆஃப் ஊட்டச்சத்துஇந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி